Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation

Mediators of Inflammation

Volumn 8, Issue 2, 1999, Pages 93-100

  Waszczykowska, Elzbieta ^a   Robak, Ewa ^a   Wozniacka, Anna ^a   Narbutt, Joanna ^a   Torzecka, Jolanta Dorota ^a   Sysa Jedrzejowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Generation O2 ; Interleukin 10; Interleukin 6; Systemic lupus erythematosus activity; Tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; RADICAL; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; GRANULOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAST CELL; OXYGENATION; PATHOGENESIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033051917     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359990586     Document Type: Article

References (35)

1. 1. Paty JG, Sienknecht CW, Townes AS, Hanissian AS, Miller JB, Masi AT, Impaired cell-mediated immunity in systemic lupus erythematosus (SLE) A controlled study of 23 untreated patients. Am J Med 1975: 59: 769-779.
2. 2. Shoenfeld Y, Mozes E. Pathogenic idiotypes in autoimmunity; lessons from new experimental models of SLE. FASEB J 1990: 4: 2646-2651.
3. 3: Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992: 63: 10-12.
4. 4. Handwerger BS, Rus V, da Silval, Via CS. The role of cytokines in the immunopathogenesis of lupus. Springer Semin Immunopathol 1994: 16: 153-180.
5. 5. Robak E, Sysa-Jedrzejowska A, Robak T, Stepien H, Wozniacka A, Waszczykowska E. Tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and sIL-6R) serum levels in systemic lupus erythematodes. Med Inflamm 1996: 5: 435-441.
6. 6. Emilie D, Liorente L, Galanaud P. Interleukin-10, a key cytokine in inflammatory joint disease. Rev Rheum Engl Ed 1995: 62: 229-232.
7. 7. Mosmann TR, Coffiman RL. Properties and functions of interleukin-10. Adv Immunol 1994: 56: 1-26.
8. 8. Ishida H, Hastings R, Karney J, Howard M. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 cells but not conventional B cells. J Exp Med 1992: 175: 1213-1216.
9. 9. Antonaccio F, Bassissi P. Free radicals. Chron Dermatol 1994: 4: 1017-1033.
10. 10. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994: 25: 111-121.
11. 11. Knight JA. Diseases related to oxygen derived free radicals. Ann Clin Lab Sci 1995: 25: 11-121.
12. 12. Aruoma OI. Nutrition and health aspects of free radicals and antioxidants. Food Chem Toxicol 1994: 32: 671-683.
13. 13. Liang MH, Socher SA, Larson MG, Schur PB. Reliabilily and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthr Rheum 89: 32: 1107-1118.
14. 14. Bellavite P, Dri P, Della Blamca P et al. The measurement of superoxide anion production by granulocytes in whole blood. A clinical test for the evaluation of phagocyte function and serum opsonic capacity. Eur J Clin Invest 1983: 13: 363-369.
15. 15. Houssiau FA, Lefebre C, Vaden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interlaukine 10 titers in systemic lupus erythomatosus reflect disease activity. Lupus 1995: 4: 393-395.
16. 16. Linker-Israeli M, Deans RJ, Wallanne DJ, Prehu J, Ozeri-Chan T, Klimberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythomatosus. A putative role in pathogenesis. J Immunol 1991: 147: 117-123.
17. 17. Meyer C, Huysen V, Smeeuk RTJ et al. Profiles of cytokines (TNF-α and IL-6) and acute phase proietns (CRD and α1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993: 2: 359-364.
18. 18. Robak T. Biologia interleukiny 6 (IL-6) i jej znaczenie w patogenezie niektŪrych chorŪb. Post Hig Med Dosu' 1994: 48: 565-567.
19. 19. Suyer K, de Witt L, Content J. Glucocorticoid upregulation of high-affinity interleukin 6 receptors on human epihtelial cell Proc Natl Acad Sci USA 1990: 87: 2838-2841.
20. 20. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, VisherT, Guerne PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid athritis. J Rheum 1993: 20: 815-821.
21. 21. Al-Jandai M, Al-Balla S, Al Dallaan A, Razzioddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases. J Clin Immunol 1993: 13: 58-67.
22. 22. Spronk PE, Ter Borg EJ, Limburg PC, Kjllenberg CGM. Plasma concentration of IL-6 in systemic lupus erythematosus and indicator of disease activity. Clin Exp Immunol 1992: 85: 386-391.
23. 23. Mitamura K, Kang H, Tomita Y, Hashimoto H, Sawada S, Horie T. Impaired tumor necrosis factor alpha production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991: 85: 386-391.
24. 24. Malave I, Searles RP, Muntano J, Williams RC Jr. Production of tumor necrosis factor/cachectin by peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1989: 89: 355-361.
25. 25. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthr Rheum 1989: 32: 146-150.
26. 26. Arai K, Lee F, Miyjama A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of inflammatory responses. Ann Rev Inc 1990: 59: 783-786.
27. 27. Gordon C, Emery P. Cytokines and the acute phase response in SLE, Lupus 1993: 2: 245-247.
28. 28. Brennan DC, Yui MA, Wuthrich RP, Keley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. J Immunol 1989: 143: 3470-3475.
29. 29. Liorente L, Zou W, Levy L et al. Role of interleukin 10 in B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythomatosus. J Exp Med 1995: 181: 839-844.
30. 30. Llorente L, Richaud-Patin Y, Wjidens J et al. Spontaneous production of interleukin 10 by B lymphocytes and monocytes in systemic lupus erythomatosus. Eur Cytokine Netu' 1993: 4: 421-424.
31. 31. Llorente L, Richaud-Patin Y, Coudere J et al. Dysregulation of IL-10 production in relatives of patients with systemic lupus erythomatosus. Arthritis Rheum, 1997; 40: 1429-1435.
32. 32. Barnes PJ. Reactive oxygen species and airway imflammation. Free Radic Biol Med 1990; 9; 235-243.
33. 33 Ara J, Ali R. Reactive oxygen species modified DNA fragments of varying size are the preferred antigen for human anti-DNA autoantibodies. Immunol Lett 1992: 34: 195-200.
34. 34. Witt C, Neuhans K, Winsel K, Brenke A, Hiepe F, Volk HD. Bronchoalveolar lavege in patients with systemic lupus erythomatosus: characterisation of cell activity by cytofluorometry, chemiluminescence and differential cell count. Z Erkr Atmungsorgane 1991; 176: 21-29.
35. 35. Benke PJ, Levcowitz H, Pampe J, Tozman E. Scavengers of free radical oxygen effect in the generation of low molecular weight DNA in stimulated lymphocytes from patients with systemic lupus erythomatosus. Metabolism 1990: 39: 1278-1284.